Intravesical Bcg Treatment Is Inversely Associated With The Risk Of Developing Alzheimer'S Disease Or Other Dementia Among Non-Muscle-Invasive Bladder Cancer Patients

Abstract Background : Immune system plays an important role in the pathogenesis of Alzheimer\u0027s disease (AD), but it remains unclear whether Bacillus Calmette-Guerin (BCG) may affect the risk of AD or not. Methods : Using retrospective chart review, we collected data regarding demographics, comorbidities, cancer diagnosis, BCG treatment and subsequent diagnosis of AD or other dementia in a racially/ethnically diverse cohort of NMIBC patients receiving treatment between 1984 and 2020 in the Bronx, NY. We used Cox proportional hazard models to examine association between BCG treatment and risk of incident AD or other dementia, adjusting for age, gender, race/ethnicity and major comorbidities. Results : In our cohort of 1,290 NMIBC patients, a total of 99 (7.7%) patients developed AD or other dementia during follow-up. Patients who received BCG treatment (25%) had a 60% lowered incidence of AD or other dementia (adjusted hazard ratio (HR)=0.41; 95% CI 0.21-0.80) in comparison to those who did not receive BCG. There was also suggestive evidence that the reduction in risk of AD or other dementia associated with BCG treatment was stronger in men (adjusted HR=0.34 95% CI 0.15—0.81); but not in women (adjusted HR=0.75; 95% CI 0.25—2.24). When we stratified the patients who received BCG by type of treatments, patients who received both induction and maintenance rounds of BCG had a further lowered incidence of AD or other dementia (HR=0.23; 95% CI 0.06-0.96) compared to patients who did not receive BCG. Conclusions : To our knowledge, our study is one of the first to suggest that BCG treatment is associated with a reduced risk of developing AD or other dementia in a multiethnic population, independent of significant comorbidities. Larger cohort studies are needed to corroborate our findings. Micro Abstract : BCG is a standard therapy for non-muscle-invasive bladder cancer (NMIBC). Among 1,290 racially diverse NMIBC patients, those who received BCG treatment (25%) had a 60% lowered risk of Alzheimer\u0027s Disease or other dementia compared to patients who did not receive BCG. Our findings corroborate prior results from a retrospective study from Israel that the BCG\u0027s could be implicated in immune responses leading to lower risk of AD.